DURHAM — Pique Therapeutics, which is developing an immunotherapy to fight lung cancer, has raised more than $800,000 of an equity and debt round aimed at $999,999, according to a regulatory filing.

Thirteen investors invested so far in a round open since 2017, according to the filing.

Piedmont Angel Network and the Wilmington Investors Network led the company’s A round in 2009.

It’s lead drug, PT 107, showed a dramatic extension of overall survival” in patients suffering from late-stage non-small cell cancer in clinical trials.

Fighting Cancer: Startup Pique Therapeutics’ Lead Drug Candidate Shows Promise as a Vaccine

Biopharma startup Pique Therapeutics closes on first funds of ‘A’ round